Farah Champsi, Director at Kite Pharma, Inc. (KITE), sold 230,652 shares at $82.48 ($19.0M) on 2017-04-17, disclosed to the SEC on 2017-04-17.
Open-market sale of $19.0M KITE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.39 | 72,275 | $6.0M | 31.3% |
| 2 | $82.39 | 72,275 | $6.0M | 31.3% |
| 3 | $82.48 | 43,001 | $3.5M | 18.7% |
| 4 | $82.48 | 43,001 | $3.5M | 18.7% |
| 5 | $83.06 | 100 | $8K | 0.0% |
| Total | $82.42 avg | 230,652 |
| $19.0M |
| 100% |
| Filing → |
| KITE | SELL | 2017-04-26 | $20.5M | — | Filing → |
| KITE | SELL | 2015-07-02 | $41.4M | — | Filing → |
| CMRX | SELL | 2013-10-23 | $6.9M | — | Filing → |